Jiangsu Hengrui Medicine Co., Ltd
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- -
- Established
- 1970-01-01
- Employees
- -
- Market Cap
- $38.9B
A Study of Irinotecan Liposome in Advanced Pancreatic Cancer
Phase 1
Completed
- Conditions
- Advanced Pancreatic Cancer
- Interventions
- First Posted Date
- 2021-03-15
- Last Posted Date
- 2025-04-29
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 41
- Registration Number
- NCT04796948
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China
A Clinical Study of SHR8554 Injection for the Treatment of Pain After Orthopedic Surgery
- First Posted Date
- 2021-03-12
- Last Posted Date
- 2021-08-12
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 192
- Registration Number
- NCT04794738
- Locations
- 🇨🇳
Shanghai Jiaotong University School of Medicine,Renji Hospital, Shanghai, Shanghai, China
Multi-dose, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DDO-3055 Tablets in Healthy Subjects.
Phase 1
- Conditions
- Renal Anemia
- Interventions
- Drug: DDO-3055 tablets；Placebo
- First Posted Date
- 2021-03-01
- Last Posted Date
- 2021-03-01
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 36
- Registration Number
- NCT04775615
A Clinical Study of SHR8554 Injection for the Treatment of Pain After Abdominal Surgery.
- First Posted Date
- 2021-02-23
- Last Posted Date
- 2022-07-06
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 528
- Registration Number
- NCT04766463
- Locations
- 🇨🇳
Union Hospital Affiliated to Tongji Medical Collage Huazhong University of Science and Technology, Wuhan, Wuhan, China
Hetrombopag for Pediatric Patients With Chronic Immune Thrombocytopenia
Phase 3
Active, not recruiting
- Conditions
- Immune Thrombocytopenia
- Interventions
- Drug: Placebo
- First Posted Date
- 2021-02-04
- Last Posted Date
- 2025-04-15
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 100
- Registration Number
- NCT04737850
- Locations
- 🇨🇳
Beijing children's hospital .Capital medical university, Beijing, Beijing, China
A Drug-drug Interaction Study Of Fluzoparib (SHR3162) on Patients With Recurrent Ovarian Cancer
- First Posted Date
- 2021-01-22
- Last Posted Date
- 2023-08-14
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 33
- Registration Number
- NCT04718740
- Locations
- 🇨🇳
Hunan Cancer Hospital, Changsha, Hunan, China
Study on the Bioavailability of SHR0302 in Healthy Subjects
- First Posted Date
- 2021-01-15
- Last Posted Date
- 2021-10-20
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 24
- Registration Number
- NCT04712838
- Locations
- 🇨🇳
Xuanwu Hospital Beijing,Capital Medical University, Beijing, Beijing, China
A Trial of SHR-1701 With or Without Famitinib in Patients With Advanced or Metastatic NSCLC
Phase 2
Withdrawn
- Conditions
- Non-Small-Cell Lung Cancer
- Interventions
- Drug: SHR-1701，Famitinib
- First Posted Date
- 2021-01-07
- Last Posted Date
- 2023-06-07
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Registration Number
- NCT04699968
A Trial of HR021618 in Postsurgical Pain Management
Phase 2
- Conditions
- Postsurgical Pain Management
- Interventions
- Drug: PlaceboDrug: HR021618
- First Posted Date
- 2021-01-07
- Last Posted Date
- 2021-08-06
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 108
- Registration Number
- NCT04699175
- Locations
- 🇨🇳
Shanghai Changhai Hospital, Shanghai, Shanghai, China
Safety and Pharmacokinetics of Fluzoparib in Healthy Subjects and Those With Impaired Liver Function
- First Posted Date
- 2021-01-05
- Last Posted Date
- 2025-04-30
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 24
- Registration Number
- NCT04694365
- Locations
- 🇨🇳
Henan Infectious Diseases Hospital, Zhengzhou, Henan, China
© Copyright 2025. All Rights Reserved by MedPath